Ecolyse: Award-Winning Bacterial Remediation
Ecolyse, a company developing industrial bacterial remediation
products that offer immense and unparalleled potential for reducing
ecological and environmental impact of human activities, recently took
home the 2012 ‘Disrupt-o-Meter’ Award at the BlueTech Forum Water
Technology Conference. Ecolyse harnesses the power of Mother Nature to
control industrial microbial contamination in the energy, biofuel, and
water industries by utilizing bacteriophage, natural bacterial
predators. Currently, most industrial bacterial problems, such as pipe
corrosion, are combated using toxic biocides or antibiotics.
Approximately $4 billion/year is spent on biocides to eliminate
microbial induced corrosion and often, these biocides are ineffective,
toxic to handle, and can risk spilling into the environment. Ecolyse’s
phage product seeks to either compliment and/or eliminate the use of
these toxic biocides.
After receiving an NSF Phase I SBIR grant, Ecolyse worked with Larta
to develop a commercialization plan. Sarah Duggleby, Product Manager,
says “Larta’s CAP was invaluable in providing instruction and feedback
on our commercialization plan.” The company was soon on the fast track
to large scale commercial success with two major partnerships with large
chemical and service providers to research treating specific bacterial
contamination problems after proven success in the lab. They are also
receiving wide spread industry acclaim, and were awarded the “Rising
Venture Energy & Clean Technology Company” at the 2011 Rice Alliance
Energy & Clean Technology Venture Forum.
Bright Outcome Uses Patient Reported Outcomes to Improve Patient Care
, a 2007-2008 Larta NIH-CAP participant, sought help with bringing their
Patient Reported Outcomes (PRO) system into clinical practice. Thanks to Larta’s
NIH-CAP, Bright Outcome was able to establish key partnerships with the NIH
PROMIS initiative, university hospitals, and research centers. Bright Outcome
CEO DerShung Yang states, “We simply cannot be where we are today without the
tremendous help that we received from CAP.” Read the full story here
Monsanto Acquires Divergence
Monsanto Company, a leading global provider of technology-based solutions and agricultural products, acquired Larta alum Divergence, Inc
. Divergence, which develops innovative biotechnology traits for parasitic nematode control and nematicides, presented in the 2009 Ag Innovation Showcase and participated in Larta’s USDA and NSF Commercialization Assistance Programs. These experiences with Larta helped Divergence to strengthen their network and refocus their marketing. Divergence CEO Derek Rapp insists “The Ag Showcase was key to bringing new relationships to the table; some relationships formed could have even resulted in deals. Through refining our pitch presentation and value proposition, the mentoring aspect of the Ag Showcase helped us to better understand our story and thus better promote Divergence.”
View More Success Stories!
"Our Larta advisor has been flexible, well informed and highly creative
in his approach to adapting his experience to our particular project and
company capabilities- I never feel like we are getting a cookie-cutter
or canned series of responses during interactions."
Steve Lynch, Director of Learning Solutions,
(Larta) seminar had a profound impact on the fundraising strategy and
methodology of our company. As a result, we were able to close a $1.2M series
A investment round. Positive momentum seems to build on itself, and several
more angels, and industry sources have expressed interest in our company."
Daniel Billing, CEO,
Innovent Medical Solutions
"The Larta consultants were essential in our success at securing phase II NSF funding on our commercialization plan. Since my colleagues and I had never gone through this process before, we learned a great deal for the next time we may submit a phase II proposal to NSF or any other government agency."
Cary Supalo, CEO,
"We would like to thank Larta Institute for guiding us to commercialize our veterinary diagnostic test kits. The “Commercialization Assistance Program” has been a great success and we managed to make some key contacts that may help the company to grow internationally."
Do Yew Tan,
Asia-Pacific Special Nutrients
"The NIH-CAP provided us with high-caliber consulting work. Our Principal Advisor helped refine our roadshow presentation during our participating in the CAP program. With Larta’s assistance we were able to clearly communicate our vision and commercialization strategy to potential investors. Most significantly, the NIH-CAP has allowed us to commercialize on a global scale."
Mitchell Sanders, CEO,
"We've benefited immensely through Larta's mentoring as well as participating in the Ag Innovation Showcase 2011 where we had the opportunity to meet key opinion leaders of the AgBio ecosystem. As a direct result of this, we are now discussing a key strategic project with Life Technologies, a US company that’s a world leader in gene sequencing technologies."
Huan Ung, CEO,
GS Biotech S/B
commercialization assistance program has been immensely valuable to us. The
documents we developed as part of our
commercialization strategy report, most importantly our Commercialization
Road Map and Barriers to Market Entry, have already been put to good use in
our efforts to secure commercialization financing. As a young business, when
we think about our key success factors, the Larta CATP and our mentor are at
the top of the list."
Edie Johnston, Founder,
Biosciences benefited greatly through its work with Larta. Our principal
advisor provided highly valuable feedback on our corporate strategy,
presentation and fundraising
program. While still working with Larta, Wave 80 consummated a $1
million angel financing round. Since completing the program, we
continue to work closely with our advisor and look forward to the next phase
of work with Larta."
Daniel Laser, CEO,
Wave 80 Biosciences
the Larta sessions, we got the chance to review the challenges facing us as
well as opportunities for our growth… Larta mentors have helped us focus and
define methods to meet our goals."
Nimrod Lev, CEO,
"The Larta Institute Global Bridge™ program was an excellent experience. We were able to discuss with investors and business advisers who provided us with knowledge of the business. Some of the points that we discussed were very important for my new international venture FKx Inc."
was integral in aiding in the development of our NSF commercialization plan.
Often times I wonder if Advantageous Systems would have been as successful as
we are now if it weren't for the help of Larta and our principal advisor."
Adam Stein, CEO,
"This program has been very helpful for me. A company has licensed our technology and invested in conducting clinical trials and a new testing facility for EMAN. If Larta was not there, this definitely would not have been achievable."
Amin Malik Shah Abdul Majid ,
EMAN Testing and Research Laboratory
Larta PA was instrumental in providing timely, actionable, and deeply
insightful guidance that has helped our company to navigate through the
wilderness that is startup life. The PA program has been one of the best
components, and privileges , of the NSF SBIR program. For the purposes
of this startup, I have found the Larta mentorship as valuable as my time on
Wall Street as an M&A investment banker, as a consultant at McKinsey
& Co, and as a student at Wharton earning my MBA."
David Kim, CEO,
"Larta has assembled one of the best commercialization assistance advisor teams in the world and has made substantial contributions to assisting small technology firms in bringing their advanced technologies from the laboratory to commercialization."
United Environment & Energy
matter where you are in the commercialization process – there is more to
learn from the experts assembled that support the CAP program. This time
around we will use the commercialization resources and expertise to assess
the viability of another product for the product pipeline."
Richard West, President & CEO,
Advanced Liquid Logic
"Our Principal Advisor’s feedback was really helpful. Our PA brought to us with a combination of detailed expertise and practical business approach. The Larta program forced us to hone our message and develop presentations we have relied on since we graduated. The program was worth while and we are glad that we were able to participate."
R.J. Sims Preston, CEO,
"The NIH-CAP program was instrumental in the success of our company. Our advisor was a great resource and his advice was instrumental in our lead product Bio-SEAL being successfully acquired while we were in the CAP program. Larta and their entire team did a fantastic job organizing and running the program and I am still involved years after giving lectures and as a panelist."
John Fisher, CEO,
has been a beneficial platform for our strategic plan to be a renowned
vertically integrated Agbiotech firm. To Orchid Life, Larta Institute is
not just a trainer or mentor but is an important, long term, partner within
our ongoing vision, mission and goals."
Abdul Razak Mohd Isa,
"We were consistently pleased with the quality of instruction and consultation from Larta. We were also pleased to participate in the past forums presented by Larta. Because of the excellent guidance of the principal advisors and the Larta personnel, we have been able to successfully present VRMC to investors."
Mark Wiederhold, CEO,
Virtual Reality Medical Center